Drug intelligence / Profile preview

follitropin delta + cetrorelix

Development stage: Unknown
Lead developer: Ferring Pharmaceuticals
Modality: Recombinant Proteins and Enzymes, Peptides, Small Molecules
Administration: Subcutaneous

Overview

Follitropin delta (FE 999049) is a novel recombinant human follicle-stimulating hormone (rFSH) developed by Ferring Pharmaceuticals and marketed under the brand name REKOVELLE. It is used for controlled ovarian stimulation to develop multiple follicles in women undergoing assisted reproductive technologies such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Dosing is individualized based on body weight and serum anti-Müllerian hormone levels[5]. Cetrorelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) antagonist that inhibits premature luteinizing hormone surges during ovarian stimulation. It acts by competitively binding to GnRH receptors on pituitary cells, suppressing LH and FSH release[2][6][8]. The combination of follitropin delta with cetrorelix is used in ART protocols to optimize follicular development while preventing premature ovulation.

Brand names: REKOVELLECetrotide
Other names: recombinant human follicle-stimulating hormone + cetrorelix acetate

Targets

FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on follitropin delta + cetrorelix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on follitropin delta + cetrorelix.

Explore the full profile